BCRX vs RJF · rev $874.8M vs rev $15.91B
BioCryst Pharmaceuticals Inc (BCRX) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
RJF (RJF) common stock.
Latest reported BCRX revenue for 2025-12-31 was $874.8M. Net income was $263.9M. BCRX currently screens at market cap $1.83B.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
BCRX currently screens at market cap $1.83B. RJF currently screens at market cap $0.
Not investment advice. Open the BCRX and RJF stock pages for the full models.
Not investment advice.